SG48125A1 - Antigenes of the envelope transmembrance glcoprotein of a human retrovirus of the hiv-2 type and antigens presenting with them an immunological relationship - Google Patents

Antigenes of the envelope transmembrance glcoprotein of a human retrovirus of the hiv-2 type and antigens presenting with them an immunological relationship

Info

Publication number
SG48125A1
SG48125A1 SG1996007178A SG1996007178A SG48125A1 SG 48125 A1 SG48125 A1 SG 48125A1 SG 1996007178 A SG1996007178 A SG 1996007178A SG 1996007178 A SG1996007178 A SG 1996007178A SG 48125 A1 SG48125 A1 SG 48125A1
Authority
SG
Singapore
Prior art keywords
glycoprotein
type
envelope
hiv
glcoprotein
Prior art date
Application number
SG1996007178A
Inventor
Ara Hovanessian
Bernard Krust
Anne Laurent
Luc Montagnier
Maire-Anne Rey
Original Assignee
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR8906322A external-priority patent/FR2646854A1/en
Priority claimed from US07/356,459 external-priority patent/US5208321A/en
Application filed by Pasteur Institut filed Critical Pasteur Institut
Publication of SG48125A1 publication Critical patent/SG48125A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention relates to an antigenic glycoprotein gp80 characterized by the following properties: it has a molecular weight (PM) close to 80 kDa; it is recognized by polyclonal antibodies directed against the glycoprotein gp300; it includes in association in the form a dimer to entities of the envelope transmembrane glycoprotein gp36, coded by the genome of a human retrovirus of the type HIV-2, susceptible of causing SLA or AIDS in human beings, or any glycoprotein having a molecular weight of the same order of magnitude, capable of forming an immunological complex of the type antigene-antibody, with antibodies directed against said gp80. The invention also relates to antibodies directed against said glycoprotein. It also relates to diagnostic and vaccination applications.
SG1996007178A 1989-05-12 1990-05-11 Antigenes of the envelope transmembrance glcoprotein of a human retrovirus of the hiv-2 type and antigens presenting with them an immunological relationship SG48125A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8906322A FR2646854A1 (en) 1989-05-12 1989-05-12 Antigens of the envelope transmembrane glycoprotein of a HIV-2 type human retrovirus, antigens exhibiting an immunological relationship with them
US07/356,459 US5208321A (en) 1988-06-09 1989-05-25 HIV-2 transmembrane glycoprotein homodimer (GP 80)

Publications (1)

Publication Number Publication Date
SG48125A1 true SG48125A1 (en) 1998-04-17

Family

ID=26227325

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1996007178A SG48125A1 (en) 1989-05-12 1990-05-11 Antigenes of the envelope transmembrance glcoprotein of a human retrovirus of the hiv-2 type and antigens presenting with them an immunological relationship

Country Status (11)

Country Link
EP (1) EP0424519B1 (en)
JP (5) JP3534746B2 (en)
AT (1) ATE136789T1 (en)
CA (1) CA2032505C (en)
DE (1) DE69026569T2 (en)
DK (1) DK0424519T3 (en)
ES (1) ES2085908T3 (en)
HK (1) HK219796A (en)
OA (1) OA09634A (en)
SG (1) SG48125A1 (en)
WO (1) WO1990013314A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256561A (en) * 1991-12-20 1993-10-26 Abbott Laboratories Monoclonal antibody to HIV-2 and uses thereof
FR2692898B1 (en) * 1992-06-30 1995-06-02 Centre Nat Rech Scient Method for obtaining membrane proteins, and use of these proteins for diagnostic or vaccination purposes.
JP2013040148A (en) * 2011-08-19 2013-02-28 Asahi Kasei Corp Sialyloligosaccharide peptide immobilization bead

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2150897T3 (en) * 1986-01-22 2000-12-16 Pasteur Institut RECOMBINANT MANUFACTURING PROCEDURE OF PROTEINS DERIVED FROM HIV-2 AND CELL CULTURE THAT EXPRESSES HIV-2 PROTEINS.
EP0269520A3 (en) * 1986-11-21 1988-08-24 Institut Pasteur Retrovirus of the type hiv-2, susceptible to provoke aids, and its antigenic and nucleic-acid constituents
ATE154808T1 (en) * 1987-01-16 1997-07-15 Pasteur Institut PEPTIDES WITH THE IMMUNOLOGICAL PROPERTIES OF HIV-2
FR2620030B1 (en) * 1987-09-07 1990-03-23 Transgene Sa VECTOR FOR THE EXPRESSION OF PROTEINS OF HIV-2 VIRUS, A CAUSAL AGENT FOR AIDS, CELL CULTURE INFECTED OR TRANSFORMED THROUGH THIS VECTOR, PROTEINS OBTAINED, VACCINE AND ANTIBODIES OBTAINED

Also Published As

Publication number Publication date
JP2005170949A (en) 2005-06-30
JP3833681B2 (en) 2006-10-18
WO1990013314A3 (en) 1990-12-27
JP2008156350A (en) 2008-07-10
EP0424519A1 (en) 1991-05-02
JP2006213702A (en) 2006-08-17
EP0424519B1 (en) 1996-04-17
JP2003146999A (en) 2003-05-21
JP4174591B2 (en) 2008-11-05
DK0424519T3 (en) 1996-05-13
JP4423374B2 (en) 2010-03-03
DE69026569T2 (en) 1996-09-05
JPH03506042A (en) 1991-12-26
ATE136789T1 (en) 1996-05-15
OA09634A (en) 1993-04-30
DE69026569D1 (en) 1996-05-23
CA2032505A1 (en) 1990-11-13
ES2085908T3 (en) 1996-06-16
CA2032505C (en) 2001-07-10
JP3534746B2 (en) 2004-06-07
WO1990013314A2 (en) 1990-11-15
HK219796A (en) 1997-01-03

Similar Documents

Publication Publication Date Title
MY103182A (en) Vaccines against acquired immune deficiency syndrome.
ATE92502T1 (en) ENVELOPE ANTIGENS OF HUMAN IMMUNODEFICIENCY VIRUS AND THEIR USES.
EP1630229A3 (en) Melanoma antigens
DE3855947T2 (en) Peptides with the immunological properties of HIV-2
NZ219113A (en) Hiv peptide containing epitope of the env protein
FI931393A (en) PEPTIDER FOER ANVAENDNING VID VACCINERING OCH INUKTION AV NEUTRALISERANDE MOTKROPPAR MOT HUMANT IMMUNBRISTVIRUS
SG48125A1 (en) Antigenes of the envelope transmembrance glcoprotein of a human retrovirus of the hiv-2 type and antigens presenting with them an immunological relationship
AU8010791A (en) Hiv monoclonal antibody
EP0250128A3 (en) Novel virus isolated from patients with aids
GR3026310T3 (en) Proteins and glycoproteins of the HIV-2 EHO retrovirus antibodies direced against them - application for the diagnosis.
PT90800A (en) A PROCESS FOR THE PREPARATION OF PRECURSING ANTIGENS OF THE INVOLVING GLYCOPROTEINS OF A HUMAN HIV-2 RETROVIRUS AND ANTIGENS THAT PRESENT AN IMMULIOUS ANALOGY WITH THESE LAST AND THEIR APPLICATION TO THE DIAGNOSIS
SU1739559A1 (en) TREATMENT OF APHTAE EPIZOOTICAE VIRUS TYPE O, USED TO MAKE DIAGNOSTIC SERIES AND ANTIGEN DRUGS
CA2046016A1 (en) Hiv monoclonal antibody